These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10219714)

  • 21. Classical swine fever vaccines-State-of-the-art.
    Blome S; Moß C; Reimann I; König P; Beer M
    Vet Microbiol; 2017 Jul; 206():10-20. PubMed ID: 28069290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The desired field-performance characteristics of new improved vaccines for the developing world.
    de Quadros CA; Carrasco P; Olivé JM
    Int J Technol Assess Health Care; 1994; 10(1):65-70. PubMed ID: 8157462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccines and infectious disease.
    Fletcher MA; Saliou P
    EXS; 2000; 89():69-88. PubMed ID: 10997283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries.
    Walker RI
    Vaccine; 2005 May; 23(26):3369-85. PubMed ID: 15837361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines.
    Moyle PM
    Biotechnol Adv; 2017; 35(3):375-389. PubMed ID: 28288861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progress, challenges and opportunities in fish vaccine development.
    Adams A
    Fish Shellfish Immunol; 2019 Jul; 90():210-214. PubMed ID: 31039441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccines against biologic agents: uses and developments.
    Ales NC; Katial RK
    Respir Care Clin N Am; 2004 Mar; 10(1):123-46. PubMed ID: 15062232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Approaches to a vaccine against hepatitis A: development and manufacture of an inactivated vaccine.
    André FE
    J Infect Dis; 1995 Mar; 171 Suppl 1():S33-9. PubMed ID: 7876646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology.
    Rodrigues AF; Soares HR; Guerreiro MR; Alves PM; Coroadinha AS
    Biotechnol J; 2015 Sep; 10(9):1329-44. PubMed ID: 26212697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Seasonal influenza vaccines.
    Fiore AE; Bridges CB; Cox NJ
    Curr Top Microbiol Immunol; 2009; 333():43-82. PubMed ID: 19768400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [On three revolutions of vaccine].
    Kou Y
    Zhonghua Yi Shi Za Zhi; 2006 Apr; 36(2):104-8. PubMed ID: 17096989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Possibilities and limitations in veterinary vaccine development using the example of classical swine fever].
    Blome S; Gabriel C; Beer M
    Berl Munch Tierarztl Wochenschr; 2013; 126(11-12):481-90. PubMed ID: 24511823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines.
    Aida V; Pliasas VC; Neasham PJ; North JF; McWhorter KL; Glover SR; Kyriakis CS
    Front Vet Sci; 2021; 8():654289. PubMed ID: 33937377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Vaccination perspectives].
    Saliou P; Plotkin S
    Sante; 1994; 4(3):237-41. PubMed ID: 7921696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical experience with inactivated, virosomal influenza vaccine.
    de Bruijn IA; Nauta J; Cramer WC; Gerez L; Palache AM
    Vaccine; 2005 Jul; 23 Suppl 1():S39-49. PubMed ID: 16005120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole-Cell Vaccine Preparation: Options and Perspectives.
    Kumar P; Sunita ; Dubey KK; Shukla P
    Methods Mol Biol; 2021; 2183():249-266. PubMed ID: 32959248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetically engineered vaccines: an overview.
    Dertzbaugh MT
    Plasmid; 1998; 39(2):100-13. PubMed ID: 9514708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
    Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
    Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influenza vaccine: Where are we and where do we go?
    Keshavarz M; Mirzaei H; Salemi M; Momeni F; Mousavi MJ; Sadeghalvad M; Arjeini Y; Solaymani-Mohammadi F; Sadri Nahand J; Namdari H; Mokhtari-Azad T; Rezaei F
    Rev Med Virol; 2019 Jan; 29(1):e2014. PubMed ID: 30408280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.